Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab

Daniel C. Garibaldi, Richard A. Adler

Research output: Research - peer-reviewArticle

Abstract

Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways. It has been shown to prolong survival in patients with metastatic colorectal cancer. Cutaneous toxicity is relatively common because of the inhibition of EGFR of normal epidermal cells. We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy. His findings resolved within weeks of the discontinuation of the drug. Cicatricial ectropion is a potential sequela of EGFR inhibition by cetuximab and can resolve without surgical intervention with the discontinuation of this drug.

LanguageEnglish (US)
Pages62-63
Number of pages2
JournalOphthalmic Plastic and Reconstructive Surgery
Volume23
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Ectropion
Epidermal Growth Factor Receptor
Colorectal Neoplasms
Therapeutics
Cetuximab
Skin
Pharmaceutical Preparations
Dimerization
Colonic Neoplasms
Monoclonal Antibodies
Drug Therapy
Survival
Neoplasms

ASJC Scopus subject areas

  • Ophthalmology
  • Surgery

Cite this

Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. / Garibaldi, Daniel C.; Adler, Richard A.

In: Ophthalmic Plastic and Reconstructive Surgery, Vol. 23, No. 1, 01.2007, p. 62-63.

Research output: Research - peer-reviewArticle

@article{80349d7c2f0041f186524708acb39bac,
title = "Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab",
abstract = "Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways. It has been shown to prolong survival in patients with metastatic colorectal cancer. Cutaneous toxicity is relatively common because of the inhibition of EGFR of normal epidermal cells. We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy. His findings resolved within weeks of the discontinuation of the drug. Cicatricial ectropion is a potential sequela of EGFR inhibition by cetuximab and can resolve without surgical intervention with the discontinuation of this drug.",
author = "Garibaldi, {Daniel C.} and Adler, {Richard A.}",
year = "2007",
month = "1",
doi = "10.1097/IOP.0b013e31802d9025",
volume = "23",
pages = "62--63",
journal = "Ophthalmic Plastic and Reconstructive Surgery",
issn = "0740-9303",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab

AU - Garibaldi,Daniel C.

AU - Adler,Richard A.

PY - 2007/1

Y1 - 2007/1

N2 - Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways. It has been shown to prolong survival in patients with metastatic colorectal cancer. Cutaneous toxicity is relatively common because of the inhibition of EGFR of normal epidermal cells. We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy. His findings resolved within weeks of the discontinuation of the drug. Cicatricial ectropion is a potential sequela of EGFR inhibition by cetuximab and can resolve without surgical intervention with the discontinuation of this drug.

AB - Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways. It has been shown to prolong survival in patients with metastatic colorectal cancer. Cutaneous toxicity is relatively common because of the inhibition of EGFR of normal epidermal cells. We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy. His findings resolved within weeks of the discontinuation of the drug. Cicatricial ectropion is a potential sequela of EGFR inhibition by cetuximab and can resolve without surgical intervention with the discontinuation of this drug.

UR - http://www.scopus.com/inward/record.url?scp=33846459000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846459000&partnerID=8YFLogxK

U2 - 10.1097/IOP.0b013e31802d9025

DO - 10.1097/IOP.0b013e31802d9025

M3 - Article

VL - 23

SP - 62

EP - 63

JO - Ophthalmic Plastic and Reconstructive Surgery

T2 - Ophthalmic Plastic and Reconstructive Surgery

JF - Ophthalmic Plastic and Reconstructive Surgery

SN - 0740-9303

IS - 1

ER -